Skip to content

GILEAD SCIENCES, INC.

Follow

13F filer, CIK 882095, FOSTER CITY, CA

GILEAD SCIENCES, INC. reported $1,463,841,605 across 5 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-06.

Accepted , ingested 13F-HR 0001123292-26-001479

Period
2026-09-30
Reported value
$1.46B
Holdings
5
Top 10 weight
100%
New
0
Sold out
0

Stakes and trades reported after 2026-09-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • ASPE ASPEN NEUROSCIENCE INC: 13G 2,879,996 shares, 9.9% of the class, 13G filed 2026-11-06, 0001123292-26-001496Timeline
    Accepted , ingested

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001123292-26-001479, largest first. % of portfolio is the value over $1,463,841,605, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 30,061,124 shares; 2025Q1: 31,424,760 shares; 2025Q2: 31,424,760 shares; 2025Q3: 31,424,760 shares; 2025Q4: 31,424,760 shares; 2026Q1: 31,424,760 shares; 2026Q2: 31,424,760 shares; 2026Q3: 31,424,760 shares 31,424,760$812M55.45%0Timeline
LKFTLAKEFRONT BIOTHERAPEUTICS NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 16,707,477 shares; 2025Q1: 16,707,477 shares; 2025Q2: 16,707,477 shares; 2025Q3: 16,707,477 shares; 2025Q4: 16,707,477 shares; 2026Q1: 16,707,477 shares; 2026Q2: 16,707,477 shares; 2026Q3: 16,707,477 shares 16,707,477$501M34.24%0Timeline
ASMBASSEMBLY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,209,471 shares; 2025Q1: 2,209,471 shares; 2025Q2: 2,209,471 shares; 2025Q3: 4,505,391 shares; 2025Q4: 4,505,391 shares; 2026Q1: 4,505,391 shares; 2026Q2: 4,977,089 shares; 2026Q3: 4,977,089 shares 4,977,089$117M7.99%0Timeline
KYTXKYVERNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 4,126,119 shares; 2025Q1: 4,126,119 shares; 2025Q2: 4,126,119 shares; 2025Q3: 4,126,119 shares; 2025Q4: 4,126,119 shares; 2026Q1: 4,126,119 shares; 2026Q2: 4,126,119 shares; 2026Q3: 4,126,119 shares 4,126,119$28.1M1.92%0Timeline
XLOXilio Therapeutics Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 9,105,451 shares; 2025Q1: 9,105,451 shares; 2025Q2: 9,105,451 shares; 2025Q3: 9,105,451 shares; 2025Q4: 9,105,451 shares; 2026Q1: 650,389 shares; 2026Q2: 650,389 shares; 2026Q3: 650,389 shares 650,389$5.89M0.4%0Timeline

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001123292-26-001479 base2026-11-06